EBMT data show that tens of thousands of autologous stem cell transplants have now been performed and it can be assumed that the vast majority of these will be peripheral blood or bone marrow cells preserved with dimethylsulphoxide (DMSO). Until recently, there has been little information on the neurological toxicity of this agent other than headache. 1 The recent reports of Hoyt et al 2 and Hequet et al 3 suggest that this may be a more frequent problem than currently appreciated. In our unit, 208 peripheral blood and bone marrow autologous transplants have been performed between 1992 and March 2002, and we have also noted one episode of well-documented severe neurotoxicity attributed to DMSO.
The patient, a 55-year-old female with a 1 year history of IgA multiple myeloma with a partial response to four courses of cyclophosphamide, vincristine, adriamycin and methylprednisolone (C-VAMP) was also on Warfarin for a recent Hickman line-associated thrombosis and had no previous neurological toxicity. After cyclophosphamide priming, peripheral blood stem cells were frozen in autologous plasma with 10% DMSO and her transplant dose of 1.9 Â 10 6 CD34 + cells/kg was contained in a total of four bags each of 100 ml. Conditioning chemotherapy was melphalan (200 mg/m 2 ) and 24 h later the PBSCs were thawed and rapidly reinfused, one bag at a time. Premedication was with i.v. ondansetron (8 mg), hyoscine butylbromide (20 mg) and lorazepam (1 mg).
The infusion was complicated initially by vomiting; at the completion of the infusion the patient became suddenly unresponsive (Glasgow Coma Scale 4/15) with hypoxia. Pulse rate was 90/min and blood pressure 134/80, pupils were pinpoint and unreactive to light. Her posture was decerebrate with bilateral upgoing plantars and no localising neurological signs. No obvious tonic-clonic activity was noted although she had bitten her tongue and had evidence of trismus. Initially she was treated with i.v. fumazenil because of the previous lorazepam. After no response she was given diazemuls per rectum, again with no effect. An urgent CT scan of brain was unremarkable. Blood count and electrolytes were normal. Liver function tests that were normal prior to stem cell return showed elevated bilirubin 25 nmol/l (3-18) and aspartate aminotransferase 177 U/l (10-40). Alkaline phosphatase and gamma glutamyltransferase levels remained within normal limits. A coagulation screen showed a prothrombin time of 51.4 s (12-17), APTT of 85 s (24-38) and a thrombin time of 27.2 s (14-22). This abnormality was consistent with overwarfarinisation and was reversed with 3 units of fresh frozen plasma and 1 mg of vitamin K i.v.
The patient was transferred to intensive care for ventilation. Within 48 h she was extubated and at this stage she was alert but unable to move her left arm. At day 9 post reinfusion, she developed a similar decerebrate episode not requiring ventilation and was assessed by neurologists who diagnosed mid-brain stroke. Haemopoietic engraftment occurred in the routine time frame and the patient required considerable support and rehabilitation with physiotherapy and speech therapy. She is now 6 months post transplant and continues to have some residual left arm weakness and recent memory loss but is otherwise well. A follow-up MRI scan confirmed infarction in the posterior right internal capsule with areas of increased signal in the brain stem and thalamus.
In their report of the three cases out of 126 infusions, Hoyt et al 2 found two of the cases to be because of cerebral infarction and this present case supports their contention that there may be a significant risk of cerebral ischaemia with possible infarction related to DMSO infusion. It has recently been suggested that 5% DMSO is equally efficacious in preventing damage to cells undergoing freezing, 4 and we suggest that there is a need for reassessment of the toxicity of 10% DMSO and detailed re-evaluation of the use of a lesser dose.
